BBIO stock forecast
Our latest prediction for BridgeBio Pharma, Inc.'s stock price was made on the Feb. 5, 2020 when the stock price was at 35.00$.
In the short term (2weeks), BBIO's stock price should underperform the market by -2.82%. During that period the price should oscillate between -10.30% and +9.27%.
In the medium term (3months), BBIO's stock price should underperform the market by -4.98%. During that period the price should oscillate between -39.15% and +26.28%.Get email alerts
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
At the moment the company generates 27M USD in revenues.
On its last earning announcement, the company reported a loss of -2.04$ per share.
The book value per share is 2.09$
Three months stock forecastFeb. 5, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|